Campbell & Co Investment Adviser’s Viking Therapeutics VKTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.05M	Buy	+52,532	New	+$1.7M	0.11%	320
2024 Q2	–	Sell	-4,095	Closed	-$336K	–	1373
2024 Q1	$336K	Sell	4,095 -25,183	-86%	-$1.12M	0.03%	862
2023 Q4	$545K	Buy	+29,278	New	+$383K	0.05%	668
2023 Q3	–	Sell	-18,476	Closed	-$299K	–	1211
2023 Q2	$299K	Buy	+18,476	New	+$387K	0.05%	666
2022 Q1	–	Sell	-53,600	Closed	-$247K	–	925
2021 Q4	$247K	Buy	+53,600	New	+$300K	0.08%	444

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Campbell & Co Investment Adviser's VKTX Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 52,532 shares worth $2.05M. The stake represents 0.11% of the portfolio and ranks #320 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in VKTX as recently as Q1 2024.

Campbell & Co Investment Adviser first reported a position in VKTX in Q4 2021 and has held it in 5 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Campbell & Co Investment Adviser held 52,532 shares of Viking Therapeutics worth $2.05M as of Q2 2026.
Viking Therapeutics was a new Campbell & Co Investment Adviser position in Q2 2026.
Viking Therapeutics made up 0.11% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #320 holding.
Campbell & Co Investment Adviser first reported a position in Viking Therapeutics in Q4 2021 and has held it in 5 quarters since.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.